Neuroprotective molecule could improve memory and cognition, reduce Alzheimer's degradation

May 10, 2018 by Kelsey Henry, Purdue University
Graphic shows how SERCA activator may improve memory and cognition for Alzheimer’s patients by preserving calcium ion balance in neurons and offering a new therapeutic strategy for neurodegeneration drug development. A report on this study was published in Bioorganic & Medicinal Chemistry Letters. Credit: Neurodon

A Purdue University graduate and a Purdue Research Park of Northwest Indiana (NWI) startup have published a research study in Bioorganic & Medicinal Chemistry Letters that identifies a small molecule SERCA activator that may improve memory and cognition.

In the Alzheimer's disease models, the SERCA activator shows promise in reducing the cellular stress and preventing cell loss in neurons. The molecule corrects ' calcium ion balance and represents a new therapeutic strategy for neurodegeneration drug development.

"We have identified a compound that could therapeutically slow or halt Alzheimer's disease, while also demonstrating its ability to cross the blood brain barrier, provide good bioavailability and cause no identifiable off target effects," said Katie Krajnak, co-author and graduate of Purdue University Northwest's Department of Biological Sciences.

Krajnak and Russell Dahl, chief executive officer of Neurodon, LLC, co-published the study "A New Target for Alzheimer's disease: A Small Molecule SERCA Activator is Neuroprotective in vitro and Improves Memory and Cognition in APP/PS1 Mice" in Bioorganic & Medicinal Chemistry Letters. Read the study here.

"We are interested in neurodegenerative conditions such as Alzheimer's and Parkinson's diseases," Dahl said. "Brain cell loss occurs when the cells' calcium balance is disrupted. We focus on correcting intracellular calcium handling by developing that target calcium handling proteins, such as SERCA."

In the study, Dahl and Krajnak explored how a SERCA activator affects neurodegeneration. The team focused on two subjects, memory/cognition and brain cell mass, which are standard in pre-clinical Alzheimer's studies.

Dahl and Krajnak found that their molecule preserved brain cell mass and boosted memory in the treated subjects. The study details an array of tests, including the water maze test for memory, and illustrates the SERCA activator molecule's capacity for neuroprotection.

"Our focus is creating molecules that reach their target and act as a protector against cellular injury," Dahl said. "Currently, there are no drugs approved that actually slow down or halt neurodegeneration. Our ultimate product would accomplish this feat and bring the medicine to clinics."

In a previous study, the SERCA activator also produced a 60 percent reduction in Alzheimer's brain plaques, an aftereffect of treatment. The current study further validates these results by proving that the molecule also treats prevalent Alzheimer's symptoms.

"We could finally have a therapy modifying Alzheimer's disease," Krajnak said. "This molecule has the ability to rescue cells from apoptosis, or . Preventing cell death can also prevent further brain atrophy and memory loss accompanying the ."

Neurodon is a startup, located in the Purdue Research Park of NWI, working toward discovering neuroprotective drugs. Dahl and his team research treatments to different cell death illnesses, such as Alzheimer's diseases and amyotrophic lateral sclerosis (ALS).

Next, Neurodon moves forward to preclinical testing and, eventually, to develop an oral pill treating neurodegeneration. To accomplish this goal, the startup needs more researchers and/or partners.

Explore further: Diabetes drug 'significantly reverses memory loss' in mice with Alzheimer's

More information: Katherine Krajnak et al. A new target for Alzheimer's disease: A small molecule SERCA activator is neuroprotective in vitro and improves memory and cognition in APP/PS1 mice, Bioorganic & Medicinal Chemistry Letters (2018). DOI: 10.1016/j.bmcl.2018.03.052

Related Stories

Diabetes drug 'significantly reverses memory loss' in mice with Alzheimer's

January 1, 2018
A drug developed for diabetes could be used to treat Alzheimer's after scientists found it "significantly reversed memory loss" in mice through a triple method of action.

New connection sprouts between Alzheimer's disease and the immune system

May 31, 2017
Just as trimming back the branches of an overgrown plant can encourage healthy growth, a little pruning of the connections in the human brain can be a good thing during brain development. But what happens when this natural ...

Alzheimer's research—intracellular calcium store malfunction leads to brain hyperactivity

February 9, 2018
Alzheimer´s disease is the key cause of dementia in elderly patients. Those affected develop deficiencies in their abilities to learn, think logically, communicate, and to master the challenges of everyday life. To find ...

Antibiotic restores cell communication in brain areas damaged by Alzheimer's disease

November 15, 2016
New research from the Djavad Mowafaghian Centre for Brain Health at UBC has found a way to partially restore brain cell communication around areas damaged by plaques associated with Alzheimer's disease.

Experimental drug blocks toxic ion flow linked to Alzheimer's disease

December 5, 2017
An international team of researchers has shown that a new small-molecule drug can restore brain function and memory in a mouse model of Alzheimer's disease. The drug works by stopping toxic ion flow in the brain that is known ...

Blocking inflammation prevents cell death, improves memory in Alzheimer's disease

February 29, 2016
Using a drug compound created to treat cancer, University of California, Irvine neurobiologists have disarmed the brain's response to the distinctive beta-amyloid plaques that are the hallmark of Alzheimer's disease.

Recommended for you

Study clarifies ApoE4's role in dementia

September 20, 2018
ApoE4, a protein linked to both Alzheimer's disease and a form of dementia caused by damage of blood vessels in the brain, increases the risk of cognitive impairment by reducing the number and responsiveness of blood vessels ...

Machine learning IDs markers to help predict Alzheimer's

September 19, 2018
Nearly 50 million people worldwide have Alzheimer's disease or another form of dementia. These irreversible brain disorders slowly cause memory loss and destroy thinking skills, eventually to such an extent that self-care ...

Discovery could explain failed clinical trials for Alzheimer's, and provide a solution

September 19, 2018
Researchers at King's College London have discovered a vicious feedback loop underlying brain degeneration in Alzheimer's disease which may explain why so many drug trials have failed. The study also identifies a clinically ...

Air pollution may be linked to heightened dementia risk

September 18, 2018
Air pollution may be linked to a heightened risk of developing dementia, finds a London-based observational study, published in the online journal BMJ Open. The associations found couldn't be explained by factors known to ...

A new approach for finding Alzheimer's treatments

September 11, 2018
Considering what little progress has been made finding drugs to treat Alzheimer's disease, Maikel Rheinstädter decided to come at the problem from a totally different angle—perhaps the solution lay not with the peptide ...

Study prevents cognitive decline in older blacks with memory loss

September 10, 2018
With nearly twice the rate of dementia as whites, blacks are at a higher risk for developing diseases like Alzheimer's, but there has been little research on how to reduce this racial health disparity. A new study in black ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.